Key Findings from the AACR Abstract and Poster

  • Meaningful tumor uptake of 177Lu-RAD202 was observed at the initial and lowest dose level of 30 mCi, particularly in breast cancer lesions
  • 177Lu-RAD202 was generally well tolerated in the first three treated patients, with predominantly Grade 1–2 treatment-emergent adverse events
  • No dose-limiting toxicities or treatment discontinuations due to adverse events were observed
  • Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation

Poster Presentation Details

  • Title: A First-in-Class HER2-Targeted Radiopharmaceutical Therapy: Initial Findings from the Phase 0/1 HEAT Trial of 177Lu-RAD202 in HER2+ Advanced Solid Tumors
  • Abstract Number: CT046
  • Presenter: Dimitris Voliotis, M.D., Chief Medical Officer of Radiopharm Theranostics
  • Session: Poster Session
  • Dates: April 20, 2026 at 9:00 AM PT